A PSMA PET scan is an advanced imaging test that detects prostate cancer cells by targeting a protein called prostate-specific membrane antigen (PSMA). It is particularly useful for staging higher-risk prostate cancer and locating cancer that may have returned or spread after treatment.
If you or someone close to you has been diagnosed with prostate cancer, you may have heard the term PSMA PET scan from a urologist, oncologist, or nuclear medicine specialist. Unlike a conventional CT or bone scan, PSMA PET imaging is designed to look for a biological feature commonly found on prostate cancer cells, allowing doctors to identify possible cancer deposits throughout the body.
But what exactly happens during a PSMA PET scan, who needs one, and what can the results actually tell you?
On this Page
What is a PSMA PET scan?
PSMA PET is a medical imaging technique whose full name is prostate-specific membrane antigen positron emission tomography. It helps clinicians identify areas of prostate cancer by detecting a specific protein associated with prostate cells.
The protein, known as prostate-specific membrane antigen (PSMA), occurs on the outer surface of prostate cells. Its presence is often considerably greater in prostate cancer cells than in healthy prostate tissue. This difference allows PSMA to serve as a target for specialised imaging. The Society of Nuclear Medicine and Molecular Imaging (SNMMI) highlights the significantly higher levels of this protein that can be found in prostate cancer cells compared with normal prostate tissue.
To perform the scan, a radioactive tracer is administered through an intravenous injection. After entering the bloodstream, the tracer binds to cells that express PSMA. The PET scanner records the signals emitted by the tracer, allowing doctors to produce images that reveal areas where the substance has accumulated.
The National Cancer Institute (NCI) explains that PSMA PET imaging can help detect prostate cancer in the body, including cancer that has spread to other locations or returned following treatment. The findings can also provide important information to help doctors plan appropriate treatment.
In most cases, PSMA PET is performed alongside computed tomography (CT). This combined PET/CT examination brings together information about the tracer’s distribution and detailed images of the body’s internal structures, helping doctors identify the location of suspicious areas more accurately.
Why it is Used for Prostate Cancer?
PSMA PET plays an important role in assessing the location and spread of prostate cancer. By highlighting areas where PSMA-targeting tracers accumulate, the scan can help doctors investigate the extent of the disease and make informed decisions about further management.
This is particularly relevant because prostate cancer may extend beyond the prostate gland and affect other parts of the body, including:
- Pelvic lymph nodes
- Bones
- Distant lymph nodes
- Other organs in advanced disease
Conventional imaging such as CT and bone scans can miss relatively small areas of disease. Evidence from the landmark pro PSMA trial showed that PSMA PET-CT provided greater accuracy than conventional CT and bone scanning for staging men with high-risk prostate cancer.
The current European Association of Urology (EAU) guidelines recognise this advantage. For high-risk or locally advanced prostate cancer, the EAU recommends PSMA PET/CT where available because it provides more sensitive metastatic staging than conventional imaging.
When might a doctor recommend a PSMA PET scan?
1. Initial staging of high-risk prostate cancer
After a biopsy confirms prostate cancer, doctors need to establish whether the cancer is still confined to the prostate or has spread elsewhere.
For men with high-risk or locally advanced disease, PSMA PET/CT can provide valuable information before deciding between surgery, radiation, or systemic treatment. The EAU currently recommends metastatic screening with PSMA PET/CT for high-risk and locally advanced disease when it is available.
For lower-risk prostate cancer, however, a PSMA PET scan is generally not automatically required. There is also still some disagreement between guidelines about its role in newly diagnosed intermediate-risk disease.
2. Suspected recurrence after treatment
PSMA PET is also increasingly important when PSA starts rising after treatment.
For example, after radical prostatectomy, PSA should generally fall to very low or undetectable levels. If PSA subsequently becomes detectable and rises, doctors may investigate whether cancer has returned.
The 2026 EAU guidance recommends PSMA PET/CT after radical prostatectomy when PSA is above 0.2 ng/mL, and the result is expected to influence treatment decisions. PSMA PET/CT is recommended for men whose PSA levels rise again after radiotherapy and who may be eligible for salvage treatment with curative intent.
The scan can potentially show whether recurrence is:
- Localised around the prostate bed
- In pelvic lymph nodes
- In distant lymph nodes
- In the bones
- In other sites
That information can significantly change the treatment approach.
Learn more about PSA Density.
How is a PSMA PET scan performed?
The process is usually straightforward.
First, a healthcare professional places an IV into your arm. The PSMA-targeting radiotracer is then injected.
You normally wait for approximately an hour while the tracer circulates through your body and binds to PSMA-expressing tissue. You then lie on the PET/CT scanner, which takes images of your body.
SNMMI states that the actual scanning portion commonly takes around 30 minutes, although the complete appointment can take longer because of preparation and tracer uptake time.
Unlike an MRI, the scanner is relatively open, and the examination is generally not considered painful, apart from the IV injection.
Which radioactive tracer is used?
There isn’t just one PSMA PET tracer.
Different countries and imaging centres may use different radiopharmaceuticals. Examples include:
- Gallium-68 PSMA-11
- Fluorine-18 piflufolastat (Pylarify)
- Fluorine-18 flotufolastat (Posluma)
- Other fluorine-18-labelled PSMA tracers
The FDA has approved PSMA-targeted PET imaging agents for appropriate men with suspected prostate cancer metastasis or suspected recurrence based on elevated PSA.
The choice of tracer can depend on availability, local approvals, logistics and the imaging centre.
Is PSMA PET better than a CT or bone scan?
For detecting prostate cancer spread, PSMA PET can provide information that conventional imaging may miss.
The proPSMA study found that PSMA PET-CT had greater accuracy than conventional imaging for detecting pelvic nodal or distant metastatic disease in men with high-risk prostate cancer.
The EAU similarly reports that PSMA PET/CT has greater sensitivity for lymph-node and bone metastases than the traditional combination of CT and bone scanning.
That doesn’t mean PSMA PET completely replaces MRI, CT, bone scans, or biopsy. Each test answers different clinical questions, and doctors may use more than one imaging method.
Can a PSMA PET scan miss prostate cancer?
Yes.
A negative PSMA PET scan does not guarantee that there is no prostate cancer.
Very small lesions may be below the resolution of the scan. Some prostate cancers may also express relatively little PSMA and therefore may not produce strong tracer uptake.
SNMMI notes that lesions smaller than approximately 0.5 cm may not be detected and that both false-negative and false-positive results can occur.
This is important because patients sometimes assume that a negative scan means cancer has been completely ruled out.
It doesn’t.
What does PSMA uptake mean?
You may see terms such as PSMA-avid lesion, PSMA uptake, or SUV on your report.
PSMA uptake means that the tracer has accumulated in an area containing PSMA-expressing tissue. High tracer activity may indicate the presence of prostate cancer, but further clinical assessment is needed to confirm the diagnosis.
Some benign tissues and other conditions can also demonstrate PSMA uptake. That is why radiologists and nuclear medicine specialists interpret the location, pattern, and intensity of uptake alongside the patient’s clinical history.
The EANM/SNMMI PSMA PET/CT guideline provides standardised recommendations for performing and interpreting these scans.
Are there risks from a PSMA PET scan?
The scan exposes you to a small amount of ionising radiation from the CT component and the radiotracer. The radiotracer is designed to leave the body over time, primarily through urine. Serious reactions are uncommon, although individual risks can vary depending on the tracer and the patient’s circumstances.
Patients should tell their medical team if they are pregnant, could be pregnant, breastfeeding, have significant kidney problems, or have had previous reactions to relevant contrast agents, particularly if contrast-enhanced CT is planned.
Your imaging centre will provide specific preparation and aftercare instructions.
What happens after the scan?
The nuclear medicine physician or radiologist will analyse the images and produce a report.
If the scan identifies an area suspicious for cancer, the doctor may correlate it with:
- PSA level and PSA trend
- Gleason score/Grade Group
- Biopsy results
- Prostate MRI
- Previous surgery or radiation
- CT or other imaging
- Symptoms and physical examination
Sometimes an additional MRI, biopsy or repeat imaging is needed if a finding is uncertain. SNMMI specifically notes that additional testing may be required when PSMA PET findings are unclear.
Conclusion
A PSMA PET scan has changed how doctors can look for prostate cancer beyond the prostate itself. By targeting PSMA, it can provide a much clearer picture of suspected metastatic or recurrent disease and help doctors make more informed treatment decisions.
However, it is not a perfect test. A negative scan does not necessarily mean that every cancer cell has been ruled out, and suspicious findings sometimes require additional investigation. The most useful interpretation comes from putting the PSMA PET result together with PSA, biopsy findings, MRI, and the patient’s overall risk profile.
As PSMA-targeted imaging continues to develop, its role in prostate cancer staging, recurrence detection and treatment planning is likely to become even more important.
Key takeaways
- PSMA PET is a specialised imaging technique used to assess prostate cancer.
- The scan uses a radioactive tracer that binds to prostate-specific membrane antigen (PSMA).
- It helps locate suspected cancer in the prostate, lymph nodes, bones, and other areas of the body.
- It is especially useful for determining the extent of high-risk prostate cancer.
- Doctors may also use it to investigate possible recurrence when PSA levels increase after treatment.
- PSMA PET can detect disease that conventional CT and bone scans may miss.
- A negative PSMA PET does not completely rule out prostate cancer.
- False-positive and false-negative findings are possible.
- Results should be interpreted alongside PSA, biopsy, MRI, and the patient’s overall clinical picture.
- The exact tracer and availability of PSMA PET vary between countries and imaging centres.
FAQs
Is a PSMA PET scan painful?
No. The scan itself is painless. The main discomfort is usually the IV injection used to administer the radiotracer.
What is the typical duration of a PSMA scan?
The complete appointment can take a couple of hours because you need to wait for the tracer to circulate. The actual scanning commonly takes around 30 minutes.
Can PSMA Scan detect prostate cancer recurrence?
Yes. It is particularly useful for locating suspected recurrent prostate cancer when PSA rises after surgery or radiation treatment.
Is PSMA PET better than MRI?
They are different tests. MRI is particularly useful for evaluating the prostate and local anatomy, while PSMA PET is valuable for identifying PSMA-expressing disease throughout the body.
Does a positive PSMA PET mean cancer has spread?
Not necessarily. A suspicious PSMA-avid area may represent cancer, but interpretation depends on its location, uptake pattern and the rest of the patient’s clinical information.
Can PSMA PET replace a prostate biopsy?
Usually, no. PSMA PET is an imaging test and does not normally provide the tissue diagnosis obtained through biopsy. The appropriate diagnostic pathway depends on the clinical situation.
